ADHD Lisdexamfetamine IND Melatonine Molindone ALS Arimoclomol IND Sodium phenylbutyrate/tauroursodeoxycholic acid Dementia Aducanumab Depression Bupropion/dextromethorphan Esketamine IND Zuranolone Duchenne Golodirsen Vamorolone Epilepsy Brivaracetam IND Cannabidiol IND Cenobamaat Fenfluramine IND Ganaxolone Lacosamide IND Eye disorders Aflibercept IND Avacincaptad pegol Brolucizumab IND Faricimab Treatment of neovascular (wet) age-related macular degeneration (nAMD). Treatment of visual impairment due to diabetic macular oedema (DME). Lenadogene nolparvovec Pegcetacoplan IND Perfluorohexyloctane Phentolamine Ranibizumab Wet age-related macular degeneration (AMD). BS Wet age-related macular degeneration (AMD). BS Treatment of neovascular age-related macular degeneration (AMD) Reproxalap Sepofarsen Timrepigene emparvovec Headache Atogepant Dihydroergotamine Eptinezumab Lasmiditan Meloxicam / rizatriptan Rimegepant Multiple sclerosis Dimethyl fumarate Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Diroximel fumarate Ofatumumab Teriflunomide Aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis. IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Ublituximab Muscular diseases other Amifampridine G Bidridistrogene xeboparvovec Daxibotulinumtoxine A Deoxythymidine/deoxycytidine Di-deuterated ethyl linoleate Efgartigimod Ravulizumab IND Sugammadex G Neurological disorders other Cannabidiol gel/intradermaal Clazosentan Eculizumab IND Eladocagene exuparvovec Inebilizumab Remimazolam Rozanolixizumab Satralizumab Tiratricol Vutrisiran Zilucoplan Other psychiatry Dexmedetomidine Pain Bupivacaine extended release IND Buprenorphine IND Fasinumab Lidocaïne SDN037 SMA Risdiplam 5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies. Extension of indication to include treatment of patients below 2 months of age. IND Schizophrenia, psychosis, bipolar disorder Lumateperone Sleep disorders Daridorexant JZP-258 Natriumoxybaat controlled release Pitolisant